Valentina Guarneri

Jun 3, 2024 | high5oncology.tv | Valentina Guarneri |Diana Lüftner |Alessandra Gennari |Volkmar Müller

Breast cancer early - 100 seconds ENG Breast cancer early - 100 seconds multi language Breast cancer metastatic - 100 seconds ENG Endocrine therapy with Palbociclib + Trastuzumab Chemo-free regimen in HER2+ luminal breast cancer Systemic therapy of HER2+ patients with brain metastases Leptomeningeal metastases in HER2+ mBC Novel ADC-ICI combination therapy HER2+ mBC 1stL T-Dxd Low ER-receptor: endocrine therapy necessary after all? Broaden T-DXD as therapy standard for HER2low and ultra-low...

Apr 25, 2024 | nature.com | Matthew Goetz |Sara M. Tolaney |Valentina Guarneri |Miguel Cabral Martin |Miguel Martín |Nadia Harbeck | +1 more

AbstractIn monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively manage adverse events. Exploratory analyses to investigate the impact of dose reductions on efficacy were conducted.